As persistence of circulating B cells after rituximab is generally attributed to inefficient removal of tissue-resident B-lymphocytes, a deeper B cell depletion such as that obtained by targeting CD19+ cells would appear reasonable to improve IgG4-RD outcomes. The gene discussed is CD19; the disease is immunoglobulin G4-related sclerosing disease.